Company

Altimmune, Inc. (ALT)

Standardized SEC financial data for Altimmune, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001326190 · NASDAQ · Pharmaceutical Preparations.

Revenue growth (YoY)

105.0%

Return on equity

-39.2%

ROIC

-34.6%

Free cash flow

-$67.5M

Debt / equity

0.15×

Current ratio

18.55×

EPS (diluted)

$-1.00

Ratios for fiscal year 2025, standardized from SEC filings.

Income statement

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$8.2M	$4.4M	-$68K	$426K	$20K	$41K
R&D expense	$49.8M	$74.5M	$70.5M	$65.8M	$82.2M	$66.4M
SG&A expense	$13.2M	$15.4M	$17.1M	$18.1M

Balance sheet

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$116.0M	$190.3M	$111.1M	$135.2M	$37.0M	$43.8M
Total current assets	$230.3M	$204.1M	$192.8M	$209.6M	$137.3M	$278.2M
Property, plant & equipment	$1.1M	$1.4M	$1.1M	$651K

Cash flow

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$34.3M	-$78.2M	-$62.6M	-$75.8M	-$79.8M	-$67.5M
Capital expenditures	$204K	$12.1M	$126K	$47K	—	$11K
Free cash flow	-$34.5M	-$90.4M	-$62.7M	-$75.9M

Get ALT data via API

# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/ALT/financials \
  -H "X-API-Key: YOUR_KEY"

# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/ALT/income-statement?format=csv" \
  -H "X-API-Key: YOUR_KEY"

Get a free API key Use with Claude (MCP) →View ALT filings on SEC EDGAR →